SyntekaBio, Inc. (KOSDAQ:226330)

Market Cap	89.03B -1.4%
Revenue (ttm)	1.78B +1,357.8%
Net Income	-17.63B
EPS	-1,155.39
Shares Out	24.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,675
Average Volume	501,130
Open	3,700.00
Previous Close	3,700.00
Day's Range	3,590.00 - 3,800.00
52-Week Range	3,300.00 - 9,000.00
Beta	0.65
RSI	47.55
Earnings Date	Mar 20, 2026

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Employees: 52
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226330

Financial Performance

In 2024, SyntekaBio's revenue was 120.89 million, a decrease of -2.04% compared to the previous year's 123.41 million. Losses were -7.21 billion, -36.71% less than in 2023.